2019 Regional TSC and LAM Conference Series

Tuberous Sclerosis Alliance                     The LAM Foundation
       

The Tuberous Sclerosis Alliance and The LAM Foundation are co-hosting five Regional TSC & LAM Conferences in 2019
Focusing on patients and caregiversconferences will take place in Boston (April 13), St. Louis (June 15), Chicago (September 7), Atlanta (September 21), and Los Angeles (November 2) in 2019. 

These one-day conferences will feature local leading researchers and clinicians specializing in TSC and lymphangioleiomyomatosis (LAM), as well as speakers from The ARC, Child Neurology Foundation, and MassMutual discussing transition issues. They will also include networking opportunities to meet other families and individuals from the area. These full-day conferences will offer a Pediatric Track (Track 1), a Transition Track (Track 2), and an Adult Track with sessions important to adults with TSC and LAM (Track 3).

Key topics include:

  • Research updates, including upcoming clinical studies and trials for TSC and LAM
  • Seizure types and treatments (pediatric and adult)
  • Tumor growth and treatments
  • Behavior and mental health
  • Transitioning into adulthood
  • LAM
  • Genetics
  • Quality of life
  • Kidneys and angiomyolipomas

Learn more and register for each conference: 

Boston, MA: April 13, 2019plus

Register Now!

Date: April 13, 2019
Time: 11:00 AM–6:00 PM
Location: DoubleTree by Hilton
Boston North Shore
50 Ferncroft Rd.
Danvers, MA 01923

Agenda:

11:00 AM12:00 PM Check-in/Registration  
12:00 PM1:15 PM Welcome and Opening General Session: Research and Upcoming Clinical Trials

Brendan Manning, PhD
Elizabeth Thiele, MD, PhD

1:15 PM2:15 PM
Track 1TSC PediatricSeizure Types and Treatments Elizabeth Thiele, MD, PhD
Mustafa Sahin, MD, PhD
Track 2: TSC Transition AgeMedical Care Transition Guidelines and 

Toolkit (Child Neurology Society) 

Larry Brown, MD
Track 3a: LAM Specific General Session Souheil El-Chemaly, MD, MPH
Track 3b: TSC Adult—TAND: Mental Health Issues in Living with TSC as an Adult Lawrence SelterMD
2:15 PM2:30 PM BREAK  
2:30 PM3:30 PM Track 1: TSC PediatricTANDAggressive Behavior Management and Behavioral Challenges in Children with TSC
Peter Davis, MD
Track 2: TSC Transition Age—Education, Employment and Housing (ARC) The ARC Representative
Track 3a: LAM Specific General Session  Lisa Henske, MD
Track 3b: TSC Adult—Seizure Management and Quality of Life Issues  Elizabeth Thiele, MD, PhD
3:30 PM3:45 PM BREAK  
3:45 PM4:45 PM Track 1: TSC Pediatric—TAND: Autism Spectrum Disorder, Biomarkers, Therapeutic Options and Clinical Trials  Mustafa Sahin, MD, PhD
  Track 2: TSC Transition Age—Guardianship and Financial Planning (MassMutual) 
Rich Harwood
  Track 3: TSC Adult/LAM—Kidneys and Angiomyolipomas 
Elahna Paul, MD, PhD
4:45 PM5:00 PM
BREAK  
5:00 PM6:00 PM
General Session: Genetics in TSC and LAM 
David Kwiatkowski, MD, PhD

St. Louis, MO: June 15, 2019plus

Registration Opening Soon!

Date: June 15, 2019
Time: 8:30 AM–4:30 PM
Location: Washington University, Farrell Learning and Teaching Center (FLTC)
520 S Euclid Ave
St. Louis, MO 63110

Agenda (subject to change):

8:30 AM9:30 AM Check-in/Registration  
9:30 AM–10:45 AM Welcome and Opening General Session: Research and Upcoming Clinical Trials

Michael Wong, MD, PhD
Nishant Gupta, MD

10:45 AM–11:00 AM  BREAK  
11:00 AM–12:00 PM Track 1TSC PediatricSeizure Types and Treatments Laura Jansen, MD, PhD
Himanshu Kaulas, MD

Track 2: TSC Transition AgeMedical Care Transition Guidelines and 

Toolkit (Child Neurology Society) 

Rebecca Schultz, PhD, NP
Track 3a: LAM Specific General Session Nishant Gupta, MD
Track 3b: TSC Adult—TAND: Mental Health Issues in Living with TSC as an Adult Tanjala Gipson, MD
12:00 PM1:00 PM LUNCH  
1:00 PM2:00 PM Track 1: TSC PediatricTANDAggressive Behavior Management and Behavioral Challenges in Children with TSC
Tanjala Gipson, MD
Track 2: TSC Transition Age—Education, Employment and Housing (ARC) The Arc Representative
Track 3a: LAM Specific General Session  Seth Goldberg, MD
Track 3b: TSC Adult—Seizure Management and Quality of Life Issues  Michael Wong, MD, PhD
2:00 PM–2:15 PM BREAK  
2:15 PM3:15 PM Track 1: TSC Pediatric—TAND: Autism Spectrum Disorder, Biomarkers, Therapeutic Options and Clinical Trials  Tanjala Gipson, MD
  Track 2: TSC Transition Age—Guardianship and Financial Planning (MassMutual) 
MassMutual Representative
  Track 3: TSC Adult/LAM—Kidneys and Angiomyolipomas 
Adrian Shifren, MD
3:15 PM3:30 PM
BREAK  
3:30 PM4:30 PM
General Session: Genetics in TSC and LAM 
Dorothy Katherine Grange, MD

Chicago, IL: September 7, 2019plus

Registration Opening Soon!

Date: September 7, 2019
Time: 8:30 AM–4:30 PM
Location: Loyola University
1032 W. Sheridan Rd.
Chicago, IL 60660

Agenda (subject to change):

8:30 AM9:30 AM Check-in/Registration  
9:30 AM–10:45 AM Welcome and Opening General Session: Research and Upcoming Clinical Trials

Steve Roberds, PhD
Frank McCormack, MD

10:45 AM–11:00 AM  BREAK  
11:00 AM–12:00 PM Track 1TSC PediatricSeizure Types and Treatments Akira Yoshii, MD, PhD
Douglas Nordli, MD
Track 2: TSC Transition AgeMedical Care Transition Guidelines and 

Toolkit (Child Neurology Society) 

John Millichap, MD
Track 3a: LAM Specific General Session Dan Dilling, MD
Track 3b: TSC Adult—TAND: Mental Health Issues in Living with TSC as an Adult Sigita Plioplys, MD
12:00 PM1:00 PM LUNCH  
1:00 PM2:00 PM Track 1: TSC PediatricTANDAggressive Behavior Management and Behavioral Challenges in Children with TSC
Sigita Plioplys, MD
Track 2: TSC Transition Age—Education, Employment and Housing (ARC) The Arc Representative
Track 3a: LAM Specific General Session  Frank McCormack, MD
Track 3b: TSC Adult—Seizure Management and Quality of Life Issues  Saba Ahmed, MD
Patricia Ogden, APN, FNP, NP-C
2:00 PM–2:15 PM BREAK  
2:15 PM3:15 PM Track 1: TSC Pediatric—TAND: Autism Spectrum Disorder, Biomarkers, Therapeutic Options and Clinical Trials  Sigita Plioplys, MD
  Track 2: TSC Transition Age—Guardianship and Financial Planning (MassMutual) 
MassMutual Representative
  Track 3: TSC Adult/LAM—Kidneys and Angiomyolipomas 
Arlene Chapman, MD
3:15 PM3:30 PM
BREAK  
3:30 PM4:30 PM
General Session: Genetics in TSC and LAM 
Daryl Waggoner, MD

Atlanta, GA: September 21, 2019plus

Registration Opening Soon!

Date: September 21, 2019
Time: 8:30 AM–4:30 PM
Location: TBA

Agenda (subject to change):

8:30 AM9:30 AM Check-in/Registration  
9:30 AM–10:45 AM Welcome and Opening General Session: Research and Upcoming Clinical Trials

E. Martina Bebin, MD, MPA
Srihari Veeraraghavan, MD
Nishant Gupta, MD

10:45 AM–11:00 AM  BREAK  
11:00 AM–12:00 PM Track 1TSC PediatricSeizure Types and Treatments E. Martina Bebin, MD, MPA
David Wolf, MD, PhD
Track 2: TSC Transition AgeMedical Care Transition Guidelines and 

Toolkit (Child Neurology Society) 

Anne Tilton, MD
Track 3a: LAM Specific General Session Srihari Veeraraghavan, MD 
Track 3b: TSC Adult—TAND: Mental Health Issues in Living with TSC as an Adult TBA
12:00 PM1:00 PM LUNCH  
1:00 PM2:00 PM Track 1: TSC PediatricTANDAggressive Behavior Management and Behavioral Challenges in Children with TSC
TBA
Track 2: TSC Transition Age—Education, Employment and Housing (ARC) The Arc Representative
Track 3a: LAM Specific General Session  Nishant Gupta, MD
Track 3b: TSC Adult—Seizure Management and Quality of Life Issues  E. Martina Bebin, MD, MPA
2:00 PM–2:15 PM BREAK  
2:15 PM3:15 PM Track 1: TSC Pediatric—TAND: Autism Spectrum Disorder, Biomarkers, Therapeutic Options and Clinical Trials  TBA
  Track 2: TSC Transition Age—Guardianship and Financial Planning (MassMutual) 
MassMutual Representative
  Track 3: TSC Adult/LAM—Kidneys and Angiomyolipomas 
John Bissler, MD
3:15 PM3:30 PM
BREAK  
3:30 PM4:30 PM
General Session: Genetics in TSC and LAM 
Michael Gambello, MD, PhD

Los Angeles, CA: November 2, 2019plus

Registration Opening Soon!

Date: November 2, 2019
Time: 8:30 AM–4:30 PM
Location: Ronald Reagan UCLA Medical Center
757 Westwood Plaza
Los Angeles, CA 90095

Agenda (subject to change):

8:30 AM9:30 AM Check-in/Registration  
9:30 AM–10:45 AM Welcome and Opening General Session: Research and Upcoming Clinical Trials

Joyce Wu, MD
Ariss DerHovanessian, MD
Frank McCormack, MD 

10:45 AM–11:00 AM  BREAK  
11:00 AM–12:00 PM Track 1TSC PediatricSeizure Types and Treatments Joyce Wu, MD
Lily Tran, MD
Track 2: TSC Transition AgeMedical Care Transition Guidelines and 

Toolkit (Child Neurology Society) 

Rebecca Schultz, PhD, NP 
Track 3a: LAM Specific General Session Ariss DerHovanessian, MD
Track 3b: TSC Adult—TAND: Mental Health Issues in Living with TSC as an Adult Andrew Liu, MD
12:00 PM1:00 PM LUNCH  
1:00 PM2:00 PM Track 1: TSC Pediatric���TANDAggressive Behavior Management and Behavioral Challenges in Children with TSC
Shafali Jeste, MD
Track 2: TSC Transition Age—Education, Employment and Housing (ARC) The Arc Representative
Track 3a: LAM Specific General Session  Frank McCormack, MD
Track 3b: TSC Adult—Seizure Management and Quality of Life Issues  Don Phillips, MD, MPH
2:00 PM–2:15 PM BREAK  
2:15 PM3:15 PM Track 1: TSC Pediatric—TAND: Autism Spectrum Disorder, Biomarkers, Therapeutic Options and Clinical Trials  Shafali Jeste, MD
  Track 2: TSC Transition Age—Guardianship and Financial Planning (MassMutual) 
MassMutual Representative
  Track 3: TSC Adult/LAM—Kidneys and Angiomyolipomas 
Carl Schulze, MD
3:15 PM3:30 PM
BREAK  
3:30 PM4:30 PM
General Session: Genetics in TSC and LAM 
Julian Martinez, MD, PhD


Learn more about TSC and LAM: 

About Tuberous Sclerosis Complex (TSC)plus

Tuberous sclerosis complex (TSC) is a genetic disorder that causes non-malignant tumors to form in many different organs, primarily in the brain, eyes, heart, kidney, skin and lungs. The aspects of TSC that most strongly impact quality of life are generally associated with the brain: seizures, developmental delay, intellectual disability and autism. Approximately 85 percent of individuals experience seizures during their lifetime, and about one-third of these manifest as infantile spasms, a devastating form of epilepsy occurring in early childhood.  Autism occurs in approximately 50 percent of individuals with TSC, and other behavioral and psychiatric symptoms—such as aggression and anxiety—are quite common and are now known as TSC-Associated Neuropsychiatric Disorders (TAND).  The incidence and severity of the various aspects of TSC can vary widely among individuals, even between identical twins.

At least two children born each day will have tuberous sclerosis complex. Current estimates place tuberous sclerosis complex-affected births at one in 6,000. Nearly 1 million people worldwide are estimated to have TSC, with approximately 50,000 in the United States. Many cases may remain undiagnosed for years or decades due to the relative obscurity of the disease and the mild form symptoms may take in some people.

In 2000-2001, three studies reported that between 26% and 39% of women with a definite diagnosis of TSC have evidence of LAM (Costello et al., 2000; Franz et al., 2001; Moss et al., 2001).  Several subsequent studies suggested the frequency of lung involvement in adult women with TSC may be even higher, ranging from 42% to 49% (Muzykewicz et al, 2009; Adriaensen et al, 2011; Cudzilo et al., 2013).  Importantly, in many of these women the disease does not cause significant respiratory symptoms.

Because of the wide variety of symptoms associated with this disease, TSC can be considered a “linchpin” disease since breakthroughs in TSC can lead to breakthroughs in other diseases, including autism, epilepsy and even cancer.


About Lymphangioleiomyomatosis (LAM)plus

Lymphangioleiomyomatosis (LAM) is a progressive and often fatal lung disease that typically strikes young women. The average age of diagnosis is 34. LAM is characterized by an abnormal growth of smooth muscle cells in the lungs. These cells invade lung tissues, including the airways, blood and lymph vessels. Although these cells are not considered cancerous, they grow uncontrollably within the lungs. Over time, the cells produce materials that break down tissue causing the formation of cysts. The delicate architecture of the lungs is destroyed and the airflow is blocked, limiting the delivery of oxygen to the rest of the body. Ultimately women with LAM require supplemental oxygen and may face the need for a lung transplant or death.

The prevalence of LAM is difficult to know because it is frequently misdiagnosed as emphysema, bronchitis, allergies or asthma. There are 1,400 known cases of LAM in the United States and estimates that another 15,000 – 30,000 exist worldwide. Women with LAM suffer from shortness of breath, chest pain, fatigue and lung collapses.